VanEck Biotech ETF
BBH
83 hedge funds and large institutions have $87M invested in VanEck Biotech ETF in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 24 reducing their positions, and 8 closing their positions.
335% more call options, than puts
Call options by funds: $1.9M | Put options by funds: $436K
28% more capital invested
Capital invested by funds: $67.8M → $87M (+$19.1M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
1.92% more ownership
Funds ownership: 16.34% → 18.27% (+1.9%)
0% more funds holding
Funds holding: 83 → 83 (0)
46% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.5M |
| 2 |
VF
Virtu Financial
New York
|
+$3.59M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.36M |
| 4 |
Jane Street
New York
|
+$1.18M |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$863K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$830K |
| 2 |
ClearBridge Investments
New York
|
-$540K |
| 3 |
OAM
Occidental Asset Management
Burlingame,
California
|
-$432K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$422K |
| 5 |
MCM
Murphy Capital Management
Bedminster,
New Jersey
|
-$412K |
BBH Hedge Fund Activity: Q3 2018 in Review
83 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2018, worth a combined $87M — up 28% from $67.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BBH positions and 8 closed out — a net gain of 1 holder — while 13 added to existing stakes and 24 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $4.5M. The largest seller was UBS Group, cutting an estimated $830K.
- 83 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $87M of VanEck Biotech ETF stock for Q3 2018, up 28% quarter-over-quarter.
- 9 funds opened new VanEck Biotech ETF positions in Q3 2018 and 8 closed out, a net change of +1 holder.
- The largest VanEck Biotech ETF buyer in Q3 2018 was Susquehanna International Group, an estimated $4.5M added.
- The largest VanEck Biotech ETF seller in Q3 2018 was UBS Group, an estimated $830K sold.
Based on aggregated 13F filings for Q3 2018.